

Rab GTPases Bind at a Common Site within the Angiotensin II Type I Receptor Carboxyl-Terminal Tail: Evidence that Rab4 Regulates Receptor Phosphorylation, Desensitization, and Resensitization

Jessica L. Esseltine, Lianne B. Dale, and Stephen S. G. Ferguson

J. Allyn Taylor Centre for Cell Biology, Molecular Brain Research Group, Robarts Research Institute, and Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada

Received August 24, 2010; accepted October 13, 2010

ABSTRACT

The human angiotensin II type 1 receptor (AT₁R) is a member of the G protein-coupled receptor (GPCR) superfamily and represents an important target for cardiovascular therapeutic intervention. Agonist-activation of the AT₁R induces β -arrestin-dependent endocytosis to early endosomes in which the receptor resides as a protein complex with the Rab GTPase Rab5. In the present study, we examined whether other Rab GTPases that regulate receptor trafficking through endosomal compartments also bind to the AT₁R. We find that Rab4, Rab7, and Rab11 all bind to the last 10 amino acid residues of the AT₁R carboxyl-terminal tail. Rab11 binds AT₁R more effectively than Rab5, whereas Rab4 binds less effectively than Rab5. Alanine scanning mutagenesis reveals that proline 354 and cysteine 355

contribute to Rab protein binding, and mutation of these residues does not affect G protein coupling. We find that the Rab GTPases each compete with one another for receptor binding and that although Rab4 interacts poorly with the AT₁R, it effectively displaces Rab11 from the receptor. In contrast, Rab11 overexpression does not prevent Rab4 binding to the AT₁R. Overexpression of wild-type Rab4, but not Rab11, facilitates AT₁R dephosphorylation, and a constitutively active Rab4-Q67L mutant reduces AT₁R desensitization and promotes AT₁R resensitization. Taken together, our data indicate that multiple Rab GTPases bind to a motif localized to the distal end of the AT₁R tail and that increased Rab4 activity may contribute to the regulation AT₁R desensitization and dephosphorylation.

Introduction

The angiotensin II type 1 receptor (AT₁R) is a member of the G protein-coupled receptor (GPCR) superfamily, the largest family of integral membrane receptors, and represents an important pharmacological target for drug therapy in hypertension. The AT₁R is coupled through $G\alpha_{q/11}$ to the activation of phospholipase C β , resulting in the formation of diacylglycerol and inositol 1,4,5-trisphosphate and leading to the release of intracellular calcium stores and the activation of protein kinase C. Agonist activation of the AT₁R also results in the attenuation of receptor signaling as a consequence of receptor phosphorylation by G protein-coupled receptor ki-

nases and protein kinase C. Agonist activation and G protein-coupled receptor kinase-mediated phosphorylation of the AT₁R facilitates the recruitment of the cytosolic adaptor protein β -arrestin, which functions to sterically uncouple the AT₁R from the heterotrimeric G protein and targets the AT₁R for clathrin-mediated endocytosis (Benovic et al., 1987; Ferguson et al., 1995, 1996, 2001, 2007; Freedman et al., 1995; Oppermann et al., 1996; Krupnick and Benovic, 1998). Once internalized, GPCRs may be either sequestered in early endosomes, dephosphorylated and recycled back to the plasma membrane, or targeted to lysosomes for degradation (Goodman et al., 1996; Ferguson, 2001; Seachrist and Ferguson, 2003; Gáborik and Hunyady, 2004). In the case of the AT₁R, the receptor is internalized as a complex with β -arrestin and is retained in the early endosomal compartment and is not readily dephosphorylated (Anborgh et al., 2000).

The Rab subfamily of small Ras-like GTPases regulate the intracellular trafficking of proteins between intracellular compartments through their ability to regulate vesicular tar-

This work was supported by the Heart and Stroke Foundation of Ontario [Grant T-5933]; an Ontario Graduate Scholarship (to J.L.E.); a Tier I Canada Research Chair in Molecular Neurobiology (to S.S.G.F.); and the Heart and Stroke Foundation of Ontario Career Investigator Award (to S.S.G.F.).

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.
doi:10.1124/mol.110.068379.

ABBREVIATIONS: AT₁R, angiotensin II type 1 receptor; GPCR, G protein-coupled receptor; β_2 AR, β_2 -adrenergic receptor; HEK, human embryonic kidney; HBSS, HEPES-buffered saline solution; AngII, Angiotensin II; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; GFP, green fluorescent protein; AT_{1A}R, angiotensin II type 1A receptor; HA, hemagglutinin; IP, inositol phosphate.

geting, docking, and fusion (Seachrist and Ferguson, 2003; Gáborik and Hunyady, 2004). Rab protein function is in turn tightly regulated at the levels of protein expression, localization, membrane association, and activation. Different Rab isoforms regulate different aspects of intracellular trafficking such as internalization (Rab5), recycling (Rab4 and Rab11), and degradation (Rab7), and different GPCRs are known to preferentially traffic through certain Rab pathways (Seachrist et al., 2000, 2002; Hunyady et al., 2002; Dale et al., 2004; Hamelin et al., 2005; Holmes et al., 2006; Li et al., 2008; Wang et al., 2008; Parent et al., 2009). For example, Rab5a has been shown to interact with the AT₁R carboxyl-terminal tail and retain the receptor in Rab5a-positive early endosomes. Nevertheless, overexpression of either Rab7 or constitutively active Rab11 can redistribute AT₁R into either Rab7-positive late endosomes or Rab11-positive recycling endosomes, respectively (Seachrist et al., 2000; Dale et al., 2004). In addition, although AT₁R is not readily dephosphorylated and efficiently recycled, there is evidence to suggest that the receptor can be recycled via both slow (Rab11-mediated) and rapid (Rab4-mediated) pathways (Hunyady et al., 2002; Li et al., 2008). Rab binding to a GPCR is not unique to the AT₁R, as Rab11 has been shown to bind to the β_2 -adrenergic receptor (β_2 AR), thromboxane A₂ receptor, and prostacyclin receptor (Seachrist et al., 2002; Hamelin et al., 2005; Parent et al., 2009; Reid et al., 2010). Emerging evidence suggests that Rab interactions with these GPCRs are also critical for regulating both the trafficking and activity of these receptors. For example, previous studies with the β_2 AR have shown that the transit of the receptor from the Rab5-positive early endosome to the Rab4-positive recycling endosome is required for the dephosphorylation of the receptor (Seachrist et al., 2000).

In the present study, we have investigated whether other Rab GTPases (Rab4, Rab7, and Rab11) can interact with AT₁R carboxyl-terminal tail and compete with Rab5 for binding. We report here that Rab4, Rab5, Rab7, and Rab11 each compete for an overlapping site in the last 10 amino acid residues of the AT₁R carboxyl-terminal tail and that proline residue 354 and cysteine residue 355 represent important amino acid residues involved in Rab protein binding. Moreover, we find that overexpression of either wild-type or constitutively active Rab4, but not Rab11, promotes AT₁R dephosphorylation. The overexpression of a constitutively active Rab4 mutant also results in reduced AT₁R desensitization and promotes AT₁R resensitization. Taken together, our data indicate that multiple Rab GTPases are able to associate with their cargo and that the activity of the AT₁R may be regulated by the interaction of different Rab GTPases at the carboxyl-terminal Rab binding site.

Materials and Methods

Materials. [*myo*-³H]Inositol and [³²P]orthophosphate were acquired from PerkinElmer Life and Analytical Sciences (Waltham, MA). Dowex 1-X8 (formate form) resin 200 to 400 mesh was purchased from Bio-Rad Laboratories (Mississauga, ON, Canada). Rabbit anti-GST, anti-Rab4, anti-Rab5a, and anti-Rab11 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and goat anti-GST as well as enhanced chemiluminescence Western blotting detection reagents were purchased from GE Healthcare (Oakville, ON, Canada). Horseradish peroxidase-conjugated anti-rabbit and anti-goat IgG secondary antibodies were from Bio-Rad

Laboratories. The QuikChange site-directed mutagenesis kit was from Stratagene (La Jolla, CA). Rabbit anti-FLAG antibody, M2 anti-FLAG agarose, and all other biochemical reagents were purchased from Sigma-Aldrich (St. Louis, MO).

DNA Construction. An AT₁R mutant lacking the distal 10 amino acids (AT₁R-C1) was generated using the QuikChange site-directed mutagenesis kit to introduce a stop codon after residue 319 in the AT₁R carboxyl-terminal tail. Subsequently, primers were designed for mutagenesis such that amino acid residues within the last 10 amino acid residues of the AT₁R tail were mutated in pairs to alanine residues using the QuikChange site-directed mutagenesis kit.

Cell Culture. Human embryonic kidney (HEK) 293 cells were maintained in Eagle's minimal essential medium supplemented with 10% (v/v) heat inactivated fetal bovine serum (Invitrogen, Burlington, ON, Canada) and 50 μ g/ml gentamicin. Cells seeded in 100-mm dishes were transfected using a modified calcium phosphate method as described previously (Ferguson and Caron, 2004). After transfection (18 h), the cells were incubated with fresh medium and allowed to recover for 24 h for coimmunoprecipitation studies. Otherwise, they were allowed to recover for 6 to 8 h and reseeded into 24-well dishes and then grown an additional 18 h before experimentation.

Coimmunoprecipitation. HEK 293 cells were transiently transfected with FLAG-tagged AT₁R and either GST-tagged Rab4, Rab4-Q67L, Rab4-S22N, Rab5, Rab7, Rab7-Q67L, Rab7-N125I, Rab11, Rab11-Q70L, or Rab11-S25N. After transfection, the cells were incubated for 20 min in HEPES-buffered saline solution (HBSS) at 37°C with or without 100 nM AngII. The cells were then placed on ice, washed twice with ice-cold phosphate-buffered saline (PBS), and lysed with ice-cold lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 0.1% Triton X-100) containing protease inhibitors (1 mM AEBSF, 10 μ g/ml leupeptin, and 5 μ g/ml aprotinin). The lysates were placed on a rocking platform for 15 min at 4°C and centrifuged at 15,000g for 15 min at 4°C to pellet insoluble material. Cleared supernatant containing 250 μ g of protein were incubated with 25 μ l of FLAG M2-affinity beads (Sigma) for 1 h rotating at 4°C to immunoprecipitate FLAG-AT₁R. After incubation, the beads were washed twice with lysis buffer and twice with PBS, and proteins were solubilized in a 3 \times SDS sample buffer containing 2-mercaptoethanol. Samples were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and immunoblotted to identify coimmunoprecipitated GST-tagged Rab proteins using a primary polyclonal rabbit or goat anti-GST antibody (1:1000 dilution; Santa Cruz Biotechnology and GE Healthcare) followed by a horseradish peroxidase-conjugated secondary anti-rabbit antibody (1:10,000; Bio-Rad) or secondary anti-goat (1:2500; Bio-Rad). Receptor and Rab protein expression was determined by immunoblotting 10 μ g of protein from each cell lysate used for immunoprecipitation. Proteins were detected using chemiluminescence with the enhanced chemiluminescence kit from GE Healthcare.

Whole-Cell Phosphorylation. AT₁R phosphorylation was measured as described previously (Anborgh et al., 2000). HEK 293 cells were transiently transfected with FLAG-AT₁R along with either pEGFP (control), GFP-tagged Rab4, Rab4-Q67L, Rab4-S22N, Rab5, Rab5-S34N, Rab5-Q79L, Rab11, Rab11-Q70L, or Rab11-S25N. Seventy-two hours after transfection, cells were rinsed twice and incubated at 37°C for 1 h in phosphate-free HBSS (5 mM NaHCO₃, 20 mM HEPES, 11 mM glucose, 116 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO₄, and 2.5 mM CaCl₂, pH 7.4). Cells were then incubated at 37°C for 1 h in 100 μ Ci/ml [³²P]orthophosphate and treated for 10 min with and without 100 nM AngII, rinsed, and allowed to recover at 37°C for 0, 20, or 40 min in phosphate-free HBSS. Cells were placed on ice and lysates were collected in the presence of protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 10 μ g/ml leupeptin, and 5 μ g/ml aprotinin) and phosphatase-inhibitors (10 mM NaF and 10 mM Na₄P₂O₇) and incubated with M2 anti-FLAG affinity agarose for 2 to 3 h to immunoprecipitate receptor protein. Beads were washed and bound proteins were solubilized in SDS-PAGE sample buffer. Equal amounts of receptor protein, as determined by protein measurement

and flow cytometry, were separated by SDS-PAGE and receptor phosphorylation was determined via autoradiography at -80°C .

Measurement of Inositol Phosphate Formation. Desensitization of AT₁R signaling of inositol phosphate was measured as described previously (Olivares-Reyes et al., 2001) with some modifications. HEK 293 cells were transiently transfected with the cDNAs as described. Forty-eight hours after transfection, cells were incubated overnight in inositol-free Dulbecco's modified Eagle's medium with 100 $\mu\text{Ci}/\text{ml}$ [*myo*- ^3H]inositol. Cells were washed twice and incubated for 1 h in warm HBSS then preincubated for 3 min at 37°C in either HBSS (lacking LiCl) alone or with 100 nM AngII (desensitizing stimulus). After a brief acid wash (50 mM glycine and 150 mM NaCl, pH 3.0), cells were washed twice and were then incubated with either 10 mM LiCl alone or 10 mM LiCl with 100 nM AngII for 10 min. The resensitization of AT₁R-mediated IP formation was assessed in the same fashion except that desensitized cells were allowed to recover for 30 min before the second incubation with either 10 mM LiCl alone or 10 mM LiCl with 100 nM AngII for 10 min. Cells were placed on ice and the reaction was stopped with 500 μl of perchloric acid and was neutralized with 400 μl of 0.72 M KOH and 0.6 M KHCO₃. Total cellular [^3H]inositol incorporation was determined in 50 μl of cell lysate. Total inositol phosphate was purified by anion exchange chromatography using Dowex 1-X8 (formate form) 200 to 400 mesh anion exchange resin and [^3H]inositol phosphate formation was determined by liquid scintillation using a scintillation system (LS 6500; Beckman Coulter, Fullerton, CA).

Statistical Analysis. Densitometric data were normalized first for protein expression and the maximum value was set to 100, with all other values displayed as percentage thereof. One-way analysis of variance was performed to determine significance, followed by a post hoc Tukey multiple comparisons test or Bonferroni's multiple comparisons test to determine which means were significantly different ($p < 0.05$) from one another.

Results

Rab4, Rab5, Rab7, and Rab11 All Interact with the AT₁R. Previous research showed direct association between Rab5a and AT₁R, as well as colocalization of the AT₁R in Rab7- and Rab11-positive endosomes, after Rab GTPase overexpression (Seachrist et al., 2002; Dale et al., 2004). Thus, we investigated whether Rab binding to the human AT₁R C-tail was either exclusive to Rab5 or was also observed for Rab4, Rab7, and Rab11. HEK293 cells were transiently transfected with FLAG-AT₁R and either GST-tagged Rab4, Rab5, Rab7, or Rab11. We find that, similar to what we observed previously for Rab5a, each of the GST-Rab4, GST-Rab7, and GST-Rab11 proteins could be coimmunoprecipitated with the FLAG-AT₁R from HEK 293 cells (Fig. 1, A and B). We found that in the absence of agonist treatment signif-




Fig. 1. Rab4, Rab5, Rab7, and Rab11 each coimmunoprecipitate with AT₁R. A, representative immunoblot (IB) showing the coimmunoprecipitation (coIP) of GST-Rab4, GST-Rab5, GST-Rab7, and GST-Rab11 with the FLAG-AT₁R from HEK 293 cells in the absence (–) and presence (+) of 100 nM AngII treatment for 20 min. B, densitometric analysis of GST-Rab4, GST-Rab5, GST-Rab7, and GST-Rab11 coimmunoprecipitated with the FLAG-AT₁R from HEK 293 cells in the absence (–) and presence (+) of 100 nM AngII treatment for 20 min. Data represents the mean \pm S.D. of five independent experiments. Data were normalized for both individual Rab protein expression levels and normalized to maximum Rab protein binding to the AT₁R in each experiment. *, $p < 0.05$ compared with Rab5 coimmunoprecipitated with the AT₁R and correspondingly treated. C, immunoblot demonstrating the coimmunoprecipitation of endogenous Rab4 protein with the FLAG-AT₁R from HEK 293 cells in the absence (–) and presence (+) of 100 nM AngII treatment for 20 min. Rab4 coimmunoprecipitated with GFP antibody (Con) is used as a control. Data represents the mean \pm S.D. of four independent experiments. D, immunoblot demonstrating the coimmunoprecipitation of endogenous Rab5 protein with the FLAG-AT₁R from HEK 293 cells in the absence (–) and presence (+) of 100 nM AngII treatment for 20 min. Rab5 coimmunoprecipitated with GFP antibody (Con) is used as a control. Data represent the mean \pm S.D. of four independent experiments. E, immunoblot demonstrating the coimmunoprecipitation of endogenous Rab11 protein with the FLAG-AT₁R from HEK 293 cells in the absence (–) and presence (+) of 100 nM AngII treatment for 20 min. Rab11 coimmunoprecipitated with GFP antibody (Con) is used as a control. Data represents the mean \pm S.D. of four independent experiments. IP, immunoprecipitation.

icantly more GST-Rab11 and significantly less Rab4 protein could be coimmunoprecipitated with the FLAG-AT₁R, compared with GST-Rab5 (Fig. 1, A and B). Treatment of cells with 100 nM AngII to activate the FLAG-AT₁R resulted in a small and statistically insignificant increase in GST-Rab5 and GST-Rab7 binding to the receptor but had no effect on the association of either Rab4 or Rab11 (Fig. 1, A and B). We also examined whether endogenous Rab4, Rab5, and Rab11 could be coimmunoprecipitated with the FLAG-AT₁R from HEK 293 cells. We found that Rab4 could be coimmunoprecipitated and that agonist stimulation increased Rab4 coimmunoprecipitation with the FLAG-AT₁R by 1.6 ± 0.3 -fold ($p < 0.05$) (Fig. 1C). However, agonist treatment had no effect upon the coimmunoprecipitation of either Rab5 or Rab11 with the receptor (Fig. 1, D and E).

The rat AT₁A R was previously shown to preferentially bind to the GDP-bound form of Rab5 (Rab5-S34N) and the GDP-bound form of Rab11 interacted specifically with the thromboxane A₂ receptor (Seachrist et al., 2002; Hamelin et al., 2005). We found that wild-type Rab4, dominant-negative Rab4-S22N, and constitutively active Rab4-Q67L did not exhibit a preference for binding to the FLAG-AT₁R (Fig. 2A). In contrast, constitutively active Rab7-Q67L mutant exhibited




Fig. 2. Coimmunoprecipitation of wild-type (WT), dominant-negative (DN), and constitutively active (CA) Rab4, Rab7, and Rab11 GTPases with the AT₁R. **A**, representative immunoblot and densitometric analysis showing the coimmunoprecipitation of GST-Rab4 (WT), constitutively active GST-Rab4-Q67L, and dominant-negative GST-Rab4-S22N with FLAG-AT₁R from HEK 293 cells. **B**, representative immunoblot and densitometric analysis showing the coimmunoprecipitation of GST-Rab7 (WT), constitutively active GST-Rab7-Q67L, and dominant-negative GST-Rab7-N125I with FLAG-AT₁R from HEK 293 cells. *, $p < 0.05$ compared with wild-type Rab7 coimmunoprecipitated with the AT₁R. **C**, representative immunoblot and densitometric analysis showing the coimmunoprecipitation of GST-Rab11 (WT), constitutively active GST-Rab11-Q70L, and dominant-negative GST-Rab11-S25N with FLAG-AT₁R from HEK 293 cells. *, $p < 0.05$ compared with wild-type Rab11 coimmunoprecipitated with the AT₁R. Data represent the mean \pm S.D. of three to five independent experiments. All data were normalized for individual Rab protein expression levels in each experiment.

preferential binding to the FLAG-AT₁R (Fig. 2B). Unlike what was previously observed for the thromboxane A₂ receptor, wild-type Rab11 interacted with the FLAG-AT₁R, but both constitutively active Rab11-Q70L and dominant-negative Rab11-S25N mutants did not effectively interact with FLAG-AT₁R (Fig. 2C). This observation suggests that GTP hydrolysis is required for Rab11 binding to the AT₁R. Taken together, the data indicated that Rab4, Rab5, Rab7, and Rab11 each bind to the AT₁R but that the association of each of the Rab GTPases was mediated by different activation states of the GTPases.

Identification of the AT₁R Rab GTPase Binding Site.

We demonstrated previously that the deletion of the last 10 amino acid residues of the rat AT₁A R C-tail (AT₁A R-C1) resulted in a loss of AT₁A R colocalization with GFP-Rab5a (Dale et al., 2004). Therefore, we tested whether the deletion of the distal 10 amino acid residues of the human AT₁R would result in both the loss of Rab5 binding, as well as a loss of Rab4, Rab7, and Rab11 binding to a human FLAG-AT₁R-C1 construct. We found that the deletion of the last 10 amino acid residues resulted in a significant decrease in Rab4, Rab5, Rab7, and Rab11 protein that was coimmunoprecipitated with the FLAG-AT₁R-C1 mutant (Fig. 3, A–D). Therefore, we examined which amino acid residues localized with the distal AT₁R C-tail sequence KKPAPCFEVE were required for Rab4, Rab5, Rab7, and Rab11 binding to the receptor by performing alanine-scanning mutagenesis of pairs of amino acid residues (Fig. 3A). We found that Rab4, Rab5, Rab7, and Rab11 binding to FLAG-AT₁R-KK, FLAG-AT₁R-PA, FLAG-AT₁R-FE, and FLAG-AT₁R-VE mutant receptors was unaffected by alanine substitutions at the corresponding residues (Fig. 3, A–D). In contrast, Rab4, Rab5, and Rab11 were not coimmunoprecipitated effectively with the FLAG-AT₁R-PC alanine substitution mutant (Fig. 3, A, B, and D). Although Rab7 binding to the FLAG-AT₁R-PC alanine substitution mutant was reduced, binding was not statistically significantly different from control (Fig. 3C). None of the alanine substitutions to the AT₁R C-tail affected the coupling of the AT₁R to the activation of IP formation (Fig. 4). Taken together, the data suggested that proline residue 354 and cysteine residue 355 played an important role in the binding of the Rab4, Rab5, Rab7, and Rab11 GTPases to the AT₁R and that each of these different Rab GTPases bind to the same site on the receptor.

Rab GTPases Compete with Each Other for Association with AT₁R. Because Rab4, Rab5, and Rab11 interact with an overlapping site in the AT₁R C-tail and the overexpression of constitutively active Rab7 and Rab11 was previously shown to alter the intracellular trafficking of the receptor (Dale et al., 2004), we examined whether Rab GTPases compete for binding to the AT₁R. We found that the coimmunoprecipitation of GST-Rab5 with the FLAG-AT₁R could be antagonized by the overexpression of increasing amounts of HA-Rab11 protein (Fig. 5A). Moreover, despite the fact that GST-Rab4 was apparently a weak FLAG-AT₁R-interacting protein, the overexpression of HA-Rab4 effectively prevented GST-Rab11 coimmunoprecipitation with FLAG-AT₁R in an expression-dependent manner (Fig. 5B). Unexpectedly, increasing expression levels of HA-Rab11 did not result in the attenuation of GST-Rab4 binding to FLAG-AT₁R (Fig. 5C).

Rab4 but Not Rab11 Affects the Phosphorylation State and Desensitization of AT₁R Signaling. Because

Rab 4, Rab5, and Rab11 GTPases seemed to compete for a common binding site on the carboxyl-terminal tail of the AT₁R, we examined whether the overexpression of wild-type, dominant-negative, and constitutively active Rab4, Rab5, and Rab11 mutants might lead to altered AT₁R phosphorylation and dephosphorylation. Consistent with previous studies (Oppermann et al., 1996; Anborgh et al., 2000), agonist-stimulation of the AT₁R for 10 min effectively promoted the phosphorylation of the AT₁R (Fig. 6A–C). However, when agonist was washed out for 20 and 40 min, no dephosphorylation of the AT₁R was observed under control conditions (Fig. 6, A–C). In contrast, the overexpression of either wild-type Rab4 or constitutively active Rab4-Q67L significantly reduced the extent of agonist-stimulated AT₁R phosphorylation (Fig. 6A). Consistent with a role of Rab4 in promoting AT₁R dephosphorylation, overexpression of a dominant-negative

active Rab4-S22N mutant resulted in a significant increase in agonist-stimulated AT₁R phosphorylation, which was reduced to phosphorylation levels observed in control cells after agonist washout (Fig. 6A). The overexpression of wild-type Rab5 had no effect on either AT₁R phosphorylation or dephosphorylation (Fig. 6B). However, the overexpression of either constitutively active Rab5-Q79L or dominant-negative Rab5-S34N appeared to result in a trend toward increased dephosphorylation of the receptor, but the results did not reach statistical significance. The extent of agonist-stimulated AT₁R phosphorylation compared with control cells was not altered by the overexpression of either wild-type, dominant-negative Rab11-S25N or constitutively active Rab11-Q67L, and none of the Rab11 proteins resulted in AT₁R dephosphorylation after agonist washout (Fig. 6C).

Given that wild-type Rab4 and constitutively active Rab4-




Fig. 3. Identification of the Rab GTPase binding site within the AT₁R carboxyl-terminal tail. A, representative immunoblot (IB) showing the coimmunoprecipitation of Rab4 with either the wild-type (WT) AT₁R or AT₁R-C1 (1–349), AT₁R-K350A/K351A (KK), AT₁R-P352A/A353G (PA), AT₁R-P354A/C355A (PC), AT₁R-F356A/E357A (FE), and AT₁R-V358A/E359A (VE) mutants from HEK 293 cells. B, representative immunoblot showing the coimmunoprecipitation of Rab5 with either the wild-type AT₁R or AT₁R mutants from HEK 293 cells. C, representative immunoblot showing the coimmunoprecipitation of Rab7 with either the wild-type AT₁R or AT₁R mutants from HEK 293 cells. D, representative immunoblot showing the coimmunoprecipitation of Rab11 with either the wild-type AT₁R or AT₁R mutants from HEK 293 cells. Data represent the mean \pm S.D. of three to five independent experiments. Data were normalized for both individual Rab protein expression levels and Rab protein binding to the wild-type AT₁R in each experiment. *, $p < 0.05$ compared with wild-type Rab coimmunoprecipitated with the AT₁R. IP, immunoprecipitation.

Q67L lead to decreased AT₁R phosphorylation, we examined whether the expression of either wild-type or dominant-negative Rab4, Rab5, and Rab11 would alter the desensitization and resensitization of the AT₁R. To assess AT₁R desensitization, cells were pretreated with 100 nM AngII for 3 min in HBSS lacking LiCl (desensitizing stimulus), washed, and then treated with and without AngII for 10 min in HBSS containing LiCl. Receptor resensitization of AT₁R-mediated IP responses was measured in the same way except that cells were allowed to recover in the absence of agonist for 30 min before being subjected to a second round of agonist treatment. The pretreatment of control cells (desensitizing stim-

ulus) reduced AT₁R-stimulated IP formation to between 41 ± 4 and $48 \pm 2\%$ of control (naive) responses when cells were exposed to a subsequent 10-min exposure to AngII (Fig. 7, A–C). The overexpression of constitutively active Rab4-Q67L significantly reduced the extent of AT₁R desensitization and increased the extent of AT₁R resensitization (Fig. 7A). The overexpression of the constitutively active Rab5-Q67L mutant did not alter AT₁R desensitization but facilitated the resensitization response (Fig. 7B). None of the other Rab constructs had any effect on AT₁R desensitization and resensitization. Taken together, these results indicate that Rab4 binding, but not Rab11 binding, to the AT₁R carboxyl-terminal tail alters the phosphorylation status of the AT₁R leading to reduced AT₁R desensitization.




Fig. 4. Agonist-stimulated AT₁R inositol phosphate formation. Shown is agonist-stimulated (100 nM AngII, 10 min) inositol phosphate formation mediated by either the wild-type (WT) FLAG-AT₁R or FLAG-AT₁R-C1 (1–349), FLAG-AT₁R-K350A/K351A (KK), FLAG-AT₁R-P352A/A353G (PA), FLAG-AT₁R-P354A/C355A (PC), FLAG-AT₁R-F356A/E357A (FE), and FLAG-AT₁R-V358A/E359A (VE) mutants from HEK 293 cells. Data represents the mean \pm S.D. of three independent experiments.




Fig. 5. Competition between Rab GTPases for coimmunoprecipitation with FLAG-AT₁R. A, representative immunoblots (IB) and densitometric analysis of the coimmunoprecipitation of GST-Rab5 with FLAG-AT₁R in the absence or presence of increasing amounts of HA-Rab11. *, $p < 0.05$ compared with GST-Rab5 coimmunoprecipitated with the AT₁R in the absence of HA-Rab11. B, representative immunoblots and densitometric analysis of the coimmunoprecipitation of GST-Rab11 with FLAG-AT₁R in the absence or presence of increasing amounts of HA-Rab4. *, $p < 0.05$ compared with GST-Rab11 coimmunoprecipitated with the AT₁R in the absence of HA-Rab4. C, representative immunoblots and densitometric analysis of the coimmunoprecipitation of GST-Rab4 with FLAG-AT₁R in the absence or presence of increasing amounts of HA-Rab11. *, $p < 0.05$ compared with GST-Rab4 coimmunoprecipitated with the AT₁R in the absence of HA-Rab11. Data represent the mean \pm S.D. of three to five independent experiments. Data were normalized for both GST-Rab protein expression levels and GST-Rab protein binding to the AT₁R in absence of HA-Rab. IP, immunoprecipitation.

355) within the Rab binding domain of the AT₁R carboxyl-terminal tail that are essential for the association of Rab4, Rab5, and Rab11 but not Rab7. The association of different Rab GTPases with the AT₁R carboxyl-terminal tail has different functional outcomes, Rab5 promoting the retention of the AT₁R in early endosomes (Seachrist et al., 2002), Rab7 facilitating the trafficking of the AT₁R to lysosomes (Dale et al., 2004), and Rab4 promoting the dephosphorylation and resensitization of the receptor. Taken together, our data indicate that the association of different Rab GTPases with the carboxyl-terminal tail domain of the AT₁R may regulate different functional outcomes for AT₁R signaling in tissues that may express differing levels of each of the relevant Rab GTPases, because the overexpression of a constitutively active Rab4-Q67L mutant decreases AT₁R desensitization and facilitates resensitization.

In the current study, we have demonstrated that the domain required for Rab GTPase interactions with AT₁R are identical for Rab4, Rab5, and Rab11. Previously, we identified that the Rab5 binding domain resides within the distal 10 amino acids of AT₁R carboxyl-terminal tail and that deletion of this motif resulted in altered AT₁R trafficking to lysosomes as opposed to the retention of the receptor in early endosomes (Dale et al., 2004). We have further defined the critical residues required for Rab GTPase binding to the AT₁R and show that proline 354 and cysteine 355 are essential for binding Rab4, Rab5, and Rab11. Previously, it has been shown that the dephosphorylation and resensitization

of the β_2 AR occur as the receptor transits between the Rab5-positive early endosome and the Rab4-positive rapid recycling endosome (Seachrist et al., 2000). Moreover, it has been reported that phosphorylated μ -opioid receptor is preferentially recycled through Rab4-positive endosomes (Wang et al., 2008). We find here, that the overexpression of a constitutively active Rab4-Q67L mutant decreases both AT₁R phosphorylation and desensitization and promotes the resensitization of the receptor. Thus, these data are consistent with the hypothesis that the Rab4-positive recycling endosome functions as the compartment in which GPCR dephosphorylation is mediated by phosphatases.

Several GPCRs have now been reported to associate with Rab GTPases, including the β_2 AR, thromboxane A₂ receptor, and prostacyclin receptor (Hamelin et al., 2005; Parent et al., 2009; Reid et al., 2010). However, the residues that we have identified to be essential for Rab GTPase binding to the AT₁R are not conserved in any of these GPCRs. Rab11 binding to the thromboxane A₂ receptor is mediated by residues 335 to 345, which are localized within the central region of the thromboxane A₂ receptor carboxyl-terminal tail, and Rab11 binds α -helix 8 at the proximal end of the prostacyclin receptor. In contrast, Rab11 binding to the β_2 AR involves a bipartite binding motif, with arginine 333 and lysine 348 representing the essential amino acid residues mediating Rab11 binding to the receptor (Parent et al., 2009). Thus, to date there is no clearly defined consensus motif for Rab GTPase association with GPCRs. However, previous work from our




Fig. 6. Whole-cell phosphorylation of AT₁R in the presence and absence of wild-type (WT) and mutant Rab4, Rab11, and Rab5. **A**, representative autoradiograph and densitometric analysis of AT₁R phosphorylation in absence (control) and presence of wild-type Rab4, constitutively active (CA) Rab4-Q67L, and dominant-negative (DN) Rab4-S22N mutants. HEK 293 cells expressing FLAG-AT₁R were treated with 100 nM AngII for 10 min, washed, and allowed to recover for 0 (desensitization), 20 (resensitized), and 40 (resensitized) min. Data represent the mean \pm S.D. of six independent experiments. *, $p < 0.05$ compared with corresponding control. **B**, representative autoradiograph and densitometric analysis of AT₁R phosphorylation in absence (control) and presence of wild-type Rab5, constitutively active Rab5-Q79L, and dominant-negative Rab5-S34N mutants. Data represent the mean \pm S.D. of four independent experiments. *, $p < 0.05$ compared with corresponding control. **C**, representative autoradiograph and densitometric analysis of AT₁R phosphorylation in absence (control) and presence of wild-type Rab11, constitutively active Rab11-Q70L, and dominant-negative Rab11-S25N mutants. Data represent the mean \pm S.D. of four independent experiments. *, $p < 0.05$ compared with corresponding control. NS, not stimulated.

laboratory using yeast two-hybrid screens suggest that the region of the AT₁R carboxyl-terminal tail that is proximal to the seventh transmembrane spanning domain of the AT₁R may also be involved in Rab5 binding (Seachrist et al., 2002). Thus, the fact that we do not observe complete loss of binding of the Rab GTPases to the carboxyl-terminal tail of the receptor suggests that secondary residues within the membrane proximal domain of the receptor likely also contribute in part to Rab protein binding.

Rab GTPases not only influence the intracellular trafficking and recycling of GPCRs by directly interacting with these vesicular cargo proteins, but Rab GTPases also indirectly influence the trafficking of receptors between intracellular compartments as a consequence of their intrinsic activity. After their internalization, many GPCRs have been shown to recycle to the cell surface either via the Rab4-mediated rapid pathway directly from sorting endosomes or via the Rab11-mediated slow pathway from perinuclear recycling endosomes. The recycling of other GPCRs, including the corticotropin-releasing factor receptor 1, somatostatin-3 receptor, vasopressin V2 receptor, neurokinin-1 receptor, chemokine CXCR2, m4 muscarinic acetylcholine receptor, and protease receptor, are also differentially regulated by Rab4 and Rab11 (Innamorati et al., 2001; Kreuzer et al., 2001; Schmidlin et al., 2001; Signoret et al., 2001; Fan et al., 2002; Volpicelli et al., 2002; Roosterman et al., 2003; Holmes et al., 2006). Thus, potential alterations in individual Rab GTPase protein expression may have profound effects on GPCR activity. This could occur as the consequence of either direct

competition for GPCR binding or by increasing the relative efficiency of the intracellular trafficking and membrane fusion of vesicular compartments within the cell that is regulated by the Rab GTPase. Rab GTPase protein expression and activity has been demonstrated to be regulated by a number of different signals. First, Rab1, Rab4, and Rab6 protein expression is altered in dilated cardiomyopathy model of heart failure, and overexpression of Rab4 in the heart leads to altered β_2 AR desensitization and resensitization (Wu et al., 2001; Odley et al., 2004). Second, parasitic infection of cardiomyocytes in vitro with the protozoan *Trypanosoma cruzi* results in the down-regulation of both Rab7 and Rab11 protein expression (Batista et al., 2006). Finally, insulin is able to stimulate GTP-loading of Rab11 in cardiomyocytes, indicating the potential of Rab GTPases to serve as substrates for GPCR-activated kinases such as phosphatidylinositol 3-kinase (Schwenk and Eckel, 2007). Thus, alterations in Rab GTPase expression and activity have the potential to both directly and indirectly influence GPCR signaling under both physiological and pathophysiological conditions, suggesting that these proteins may represent targets for the treatment of cardiovascular-related diseases.

In HEK 293 cells, the AT₁R is internalized to and retained in early endosomes, where it remains phosphorylated and does not recycle to the plasma membrane (Anborgh et al., 2000; Seachrist et al., 2002; Dale et al., 2004). We find that the overexpression of different Rab GTPases can specifically alter the intracellular trafficking fate of the AT₁R, with Rab7 overexpression favoring the trafficking of the receptor to




Fig. 7. Desensitization and resensitization of AT₁R-mediated inositol phosphate formation. **A**, HEK 293 cells transfected with FLAG-AT₁R with empty pEBG vector (NT), wild-type (WT) Rab4, constitutively active (CA) Rab4-Q67L, and dominant-negative (DN) Rab4-S22N mutants. **B**, HEK 293 cells transfected with FLAG-AT₁R with empty pEBG vector, wild-type Rab5, constitutively active Rab5-Q79L, and dominant-negative Rab5-S34N mutants. **C**, HEK 293 cells transfected with FLAG-AT₁R with empty pEBG vector, wild-type Rab11, constitutively active Rab11-Q70L, and dominant-negative Rab11-S25N mutants. Transfected cells were treated either with or without 100 nM AngII for 3 min in the absence of LiCl (desensitizing stimulus) and then either washed and subjected to a second treatment of 100 nM AngII for 10 min in the presence of LiCl (desensitized) or washed and allowed to recover for 30 min before a second treatment of 100 nM AngII for 10 min in the presence of LiCl (resensitized). Data were normalized for protein expression and basal IP formation and desensitized and resensitized IP responses compared with naive control cells that were not subjected to desensitizing stimulus. Data are representative of five independent experiments. *, $p < 0.05$ compared with corresponding control.

lysosomes and Rab4 overexpression favoring the dephosphorylation of the receptor. In contrast, although Rab11 effectively interacts with the AT₁R, the interaction of the wild-type Rab11 does not influence the dephosphorylation of the receptor, although it can promote plasma membrane recycling (Dale et al., 2004). It is noteworthy that Rab4 is able to effectively displace Rab11 binding to the AT₁R, despite the observation that Rab11 is more effectively coimmunoprecipitated with the receptor. Therefore, even small differences in Rab4 expression may lead to profound changes in AT₁R activity. However, Rab binding to the AT₁R, if competitive, should be reciprocal, and Rab11 protein expressed at sufficiently high levels should be able to compete for binding. It is possible that in our experiments we have not achieved Rab11 expression that can displace Rab4 from the receptor at complimentary expression levels. Moreover, the overexpression of one Rab protein may shift the receptor from one cellular compartment to another that is not available to the competing Rab protein. It is also possible that Rab GTPases selectively bind to different receptor sites depending upon their activation state, because wild-type Rab7 does not bind to the receptor as effectively as Rab7-Q70L, and wild-type Rab7 binding is not significantly impaired when the AT₁R C-tail is truncated. This may explain why we previously observed that truncation of the AT₁R C-tail resulted in the targeting of the receptor to lysosomes (Dale et al., 2004). Nevertheless, depending on the complement of Rab GTPases expressed in different tissue and cell types, it is likely that the AT₁R will exhibit differences in its functional regulation ranging from prolonged desensitization associated with impaired dephosphorylation and resensitization to rapid resensitization associated with receptor dephosphorylation.

To date, few GPCRs, including the AT₁R, β_2 AR, thromboxane A₂ receptor, and prostacyclin receptor have been shown to directly associate with members of the Rab family. Emerging evidence suggests that these interactions are critical to proper trafficking and regulation of these receptors. Understanding the role of Rabs in the regulation of GPCR redistribution into different intracellular compartments will serve to improve our understanding of the molecular and physiological consequences of GPCR signaling. It is now evident that multiple small GTP-binding proteins, including Rabs, interact with GPCRs, and future studies should reveal whether GPCRs either interact with or regulate additional components of the intracellular trafficking machinery.

Author Contributions

Participated in research design: Esseltine, Dale, and Ferguson.
Conducted experiments: Esseltine and Dale
Performed data analysis: Esseltine and Ferguson.
Wrote or contributed to the writing of the manuscript: Esseltine, Dale, and Ferguson.

References

- Anborgh PH, Seachrist JL, Dale LB, and Ferguson SS (2000) Receptor/ β -arrestin complex formation and the differential trafficking and resensitization of β_2 -adrenergic and angiotensin II type 1A receptors. *Mol Endocrinol* **14**:2040–2053.
- Batista DG, Silva CF, Mota RA, Costa LC, Meirelles MN, Meuser-Batista M, and Soeiro MN (2006) Trypanosoma cruzi modulates the expression of Rabs and alters the endocytosis in mouse cardiomyocytes in vitro. *J Histochem Cytochem* **54**:605–614.
- Benovic JL, Kühn H, Weyand I, Codina J, Caron MG, and Lefkowitz RJ (1987) Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein). *Proc Natl Acad Sci USA* **84**:8879–8882.
- Dale LB, Seachrist JL, Babwah AV, and Ferguson SS (2004) Regulation of angiotensin II type 1A receptor intracellular retention, degradation, and recycling by Rab5, Rab7, and Rab11 GTPases. *J Biol Chem* **279**:13110–13118.
- Fan GH, Lapiere LA, Goldenring JR, and Richmond A (2002) Differential regulation of CXCR2 trafficking by Rab GTPases. *Blood* **101**:2115–2124.
- Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. *Pharmacol Rev* **53**:1–24.
- Ferguson SS (2007) Phosphorylation-independent attenuation of GPCR signalling. *Trends Pharmacol Sci* **28**:173–179.
- Ferguson SS and Caron MG (2004) Green fluorescent protein-tagged β -arrestin translocation as a measure of G protein-coupled receptor activation. *Methods Mol Biol* **237**:121–126.
- Ferguson SS, Downey WE 3rd, Colapietro AM, Barak LS, Ménard L, and Caron MG (1996) Role of β -arrestin in mediating agonist-promoted G protein-coupled receptor internalization. *Science* **271**:363–366.
- Ferguson SS, Ménard L, Barak LS, Koch WJ, Colapietro AM, and Caron MG (1995) Role of phosphorylation in agonist-promoted β_2 -adrenergic receptor sequestration. Rescue of a sequestration-defective mutant receptor by β ARK1. *J Biol Chem* **270**:24782–24789.
- Freedman NJ, Liggett SB, Drachman DE, Pei G, Caron MG, and Lefkowitz RJ (1995) Phosphorylation and desensitization of the human β_1 -adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. *J Biol Chem* **270**:17953–179561.
- Gaborik Z and Hunyady L (2004) Intracellular trafficking of hormone receptors. *Trends Endocrinol Metab* **15**:286–293.
- Goodman OB Jr, Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, Keen JH, and Benovic JL (1996) β -Arrestin acts as a clathrin adaptor in endocytosis of the β_2 -adrenergic receptor. *Nature* **383**:447–450.
- Hamelin E, Thériault C, Laroche G, and Parent JL (2005) The intracellular trafficking of the G protein-coupled receptor TP β depends on a direct interaction with Rab11. *J Biol Chem* **280**:36195–36205.
- Holmes KD, Babwah AV, Dale LB, Poulter MO, and Ferguson SS (2006) Differential regulation of corticotropin releasing factor 1 α receptor endocytosis and trafficking by beta-arrestins and Rab GTPases. *J Neurochem* **96**:934–949.
- Hunyady L, Baukal AJ, Gaborik Z, Olivares-Reyes JA, Bor M, Szaszak M, Lodge R, Catt KJ, and Balla T (2002) Differential PI 3-kinase dependence of early and late phases of recycling of the internalized AT₁ angiotensin receptor. *J Cell Biol* **157**:1211–1222.
- Innamorati G, Le Gouill C, Balamotis M, and Birnbaumer M (2001) The long and the short cycle. Alternative intracellular routes for trafficking of G-protein-coupled receptors. *J Biol Chem* **276**:13096–13103.
- Kreuzer OJ, Krisch B, Déry O, Bunnett NW, and Meyerhof W (2001) Agonist-mediated endocytosis of rat somatostatin receptor subtype 3 involves β -arrestin and clathrin coated vesicles. *J Neuroendocrinol* **13**:279–287.
- Krupnick JG and Benovic JL (1998) The role of receptor kinases and arrestins in G protein-coupled receptor regulation. *Annu Rev Pharmacol Toxicol* **38**:289–319.
- Li H, Li HF, Felder RA, Periasamy A, and Jose PA (2008) Rab4 and Rab11 coordinately regulate the recycling of angiotensin II type I receptor as demonstrated by fluorescence resonance energy transfer microscopy. *J Biomed Opt* **13**:031206.
- Odley A, Hahn HS, Lynch RA, Marreez Y, Osinska H, Robbins J, and Dorn GW 2nd (2004) Regulation of cardiac contractility by Rab4-modulated β_2 -adrenergic receptor recycling. *Proc Natl Acad Sci USA* **101**:7082–7087.
- Olivares-Reyes JA, Smith RD, Hunyady L, Shah BH, and Catt KJ (2001) Agonist-induced signaling, desensitization, and internalization of a phosphorylation-deficient AT_{1A} angiotensin receptor. *J Biol Chem* **276**:37761–37768.
- Oppermann M, Freedman NJ, Alexander RW, and Lefkowitz RJ (1996) Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C. *J Biol Chem* **271**:13266–13272.
- Parent A, Hamelin E, Germain P, and Parent JL (2009) Rab11 regulates the recycling of the β_2 -adrenergic receptor through a direct interaction. *Biochem J* **418**:163–172.
- Reid HM, Mulvaney EP, Turner EC, and Kinsella BT (2010) Interaction of the human prostacyclin receptor with Rab11: characterization of a novel Rab11 binding domain within α -helix 8 that is regulated by palmitoylation. *J Biol Chem* **285**:18709–18726.
- Roosterman D, Schmidlin F, and Bunnett NW (2003) Rab5a and rab11a mediate agonist-induced trafficking of protease-activated receptor 2. *Am J Physiol Cell Physiol* **284**:C1319–C1329.
- Schmidlin F, Dery O, DeFea KO, Slice L, Patierno S, Sternini C, Grady EF, and Bunnett NW (2001) Dynamin and Rab5a-dependent trafficking and signaling of the neurokinin 1 receptor. *J Biol Chem* **276**:25427–25437.
- Schwenk RW and Eckel J (2007) A novel method to monitor insulin-stimulated GTP-loading of Rab11a in cardiomyocytes. *Cell Signal* **19**:825–830.
- Seachrist JL, Anborgh PH, and Ferguson SS (2000) β_2 -Adrenergic receptor internalization, endosomal sorting, and plasma membrane recycling are regulated by rab GTPases. *J Biol Chem* **275**:27221–27228.
- Seachrist JL and Ferguson SS (2003) Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases. *Life Sci* **74**:225–235.
- Seachrist JL, Laporte SA, Dale LB, Babwah AV, Caron MG, Anborgh PH, and Ferguson SS (2002) Rab5 association with the angiotensin II type 1A receptor promotes Rab5 GTP binding and vesicular fusion. *J Biol Chem* **277**:679–685.
- Signoret N, Pelchen-Matthews A, Mack M, Proudfoot AE, and Marsh M (2001) Endocytosis and recycling of the HIV coreceptor CCR5. *J Cell Biol* **151**:1281–1294.

- Volpicelli LA, Lah JJ, Fang G, Goldenring JR, and Levey AI (2002) Rab11a and myosin Vb regulate recycling of the M4 muscarinic acetylcholine receptor. *J Neurosci* **22**:9776–9784.
- Wang F, Chen X, Zhang X, and Ma L (2008) Phosphorylation state of mu-opioid receptor determines the alternative recycling of receptor via Rab4 or Rab11 pathway. *Mol Endocrinol* **22**:1881–1892.
- Wu G, Yussman MG, Barrett TJ, Hahn HS, Osinska H, Hilliard GM, Wang X, Toyokawa T, Yatani A, Lynch RA, Robbins J, and Dorn GW 2nd (2001) Increased

myocardial Rab GTPase expression: a consequence and cause of cardiomyopathy. *Circ Res* **89**:1130–1137.

Address correspondence to: Dr. S. S. G. Ferguson, Robarts Research Institute, University of Western Ontario, 100 Perth Dr., London, ON, Canada, N6A 5K8. E-mail: erguson@robarts.ca
